MetaCap

BeyondSpring (BYSI) vs Neuphoria Therapeutics (NEUP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neuphoria Therapeutics (NEUP) has outperformed BeyondSpring (BYSI) over the past year, losing 47.3% versus a loss of 82.8%. BeyondSpring is the larger company by market cap ($13.7 million vs $12.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BYSI-82.77%NEUP-47.31%
+28%-30%-88%
Nov 21, 20251 yearNov 20, 2026
BYSI-92.79%NEUP-98.49%
+13%-46%-104%
Dec 13, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BYSI versus NEUP key metrics
MetricBYSINEUP
Share price$0.33$2.35
Market cap$13.66M$12.72M
1-day change-24.49%+1.29%
YTD return-79.75%-39.43%
1-year return-82.77%-47.31%
5-year return-97.70%—
EPS (TTM)$-0.20$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$1.17M
Revenue growth (YoY)—-92.50%
Net income (latest FY)$-1.01M$-13.45M
Operating margin—-1401.09%
Net margin—-1145.66%
52-week high$2.44$5.53
52-week low$0.299$2.26
Distance from 52-week high-86.48%-57.50%
Analyst consensus—none
Average volume261.79K26.53K
Shares outstanding41.41M5.41M
Employees441
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NEUP has outperformed BYSI by 35.5 percentage points over the past year.

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Neuphoria Therapeutics

NEUP stock →

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

BYSI vs NEUP FAQ

Which is bigger, BeyondSpring or Neuphoria Therapeutics?

BeyondSpring (BYSI) is larger, with a market capitalization of $13.66M compared with $12.72M for Neuphoria Therapeutics (NEUP).

Which stock has performed better over the past year, BYSI or NEUP?

NEUP returned -47.31% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.

Are BeyondSpring and Neuphoria Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons